We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
+$131M
Cap. Flow %
5.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
CNSY
Cerenome
CNSY
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.57%
2 Healthcare 9.72%
3 Real Estate 2.82%
4 Energy 0.36%
5 Consumer Discretionary 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAPL icon
251
CALL
Apple
AAPL
$4.83T
– –
-16,212
Closed -$31.1M
AAPL icon
252
PUT
Apple
AAPL
$4.83T
– –
-16,212
Closed -$31.1M
ABUS icon
253
CALL
Arbutus Biopharma
ABUS
$1.01B
– –
-450
Closed -$967K
AGEN
254
CALL
Agenus
AGEN
$309M
– –
-77
Closed -$477K
AGEN
255
Agenus
AGEN
$309M
– –
-9,468
Closed -$548K
ALKS icon
256
Alkermes
ALKS
$7.56B
– –
-5,126
Closed -$236K
ALKS icon
257
PUT
Alkermes
ALKS
$7.56B
– –
-155
Closed -$683K
ATHE
258
CALL
Alterity Therapeutics
ATHE
$69.6M
– –
-50
Closed -$838K
ATHE
259
Alterity Therapeutics
ATHE
$69.6M
– –
-288
Closed -$48K
ATHE
260
PUT
Alterity Therapeutics
ATHE
$69.6M
– –
-4
Closed -$62K
BLUE
261
DELISTED
bluebird bio
BLUE
– –
-7,858
Closed -$2.52M
CASI
262
DELISTED
CASI Pharmaceuticals
CASI
– –
-106,522
Closed -$1.95M
CATX icon
263
Perspective Therapeutics
CATX
$312M
– –
-22,538
Closed -$496K
CORT icon
264
CALL
Corcept Therapeutics
CORT
$11.9B
– –
-400
Closed -$174K
CYTK icon
265
CALL
Cytokinetics
CYTK
$9.67B
– –
-661
Closed -$628K
FOCL
266
EDAP TMS S.A.
FOCL
$190M
– –
-23,200
Closed -$79.7K
EXAS
267
DELISTED
Exact Sciences
EXAS
– –
-54,000
Closed -$765K
EXAS
268
PUT
DELISTED
Exact Sciences
EXAS
– –
-655
Closed -$928K
GILD icon
269
Gilead Sciences
GILD
$178B
– –
-155,073
Closed -$12.1M
INSM icon
270
PUT
Insmed
INSM
$26.5B
– –
-305
Closed -$581K
INVA icon
271
Innoviva
INVA
$1.49B
– –
-42,853
Closed -$1.07M
INVA icon
272
PUT
Innoviva
INVA
$1.49B
– –
-666
Closed -$1.66M
IONS icon
273
CALL
Ionis Pharmaceuticals
IONS
$8.21B
– –
-1,584
Closed -$6.84M
IONS icon
274
PUT
Ionis Pharmaceuticals
IONS
$8.21B
– –
-2,078
Closed -$8.98M
IWM icon
275
PUT
iShares Russell 2000 ETF
IWM
$77B
– –
-890
Closed -$10.4M
9 10
11
12 13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management deployed $131M of net new capital in Q2 2014, opening 83 new positions and adding to 72 existing holdings. Its largest new stake was Weyerhaeuser: 1,950,977 shares worth $64.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 89% a quarter earlier, followed by Healthcare and Real Estate.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $7.12M trimmed.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.